What is Genesis Genomics?
Genesis Genomics operates as a global leader in the development of advanced biomarkers and the commercialization of specialized diagnostic services. At the core of its value proposition is a unique, proprietary mitochondrial technology that challenges existing paradigms in medical testing. The company has successfully transitioned from research-heavy development to a commercial phase, offering a suite of assays and services that provide actionable insights for physicians. By focusing on the intersection of mitochondrial health and clinical application, Genesis Genomics addresses critical gaps in diagnostic accuracy, positioning itself as an essential partner for healthcare providers seeking to improve patient outcomes through precision medicine.
How much funding has Genesis Genomics raised?
Genesis Genomics has raised a total of $2.8M across 2 funding rounds:
Debt
$766K
Debt
$2.1M
Debt (2010): $766K, investors not publicly disclosed
Debt (2013): $2.1M, investors not publicly disclosed
Key Investors in Genesis Genomics
Genesis Genomics
Undisclosed investor participating in the funding round.
Genesis Genomics
Undisclosed investor participating in the funding round.
Genesis Genomics
Undisclosed investor participating in the funding round.
What's next for Genesis Genomics?
With the recent influx of capital, Genesis Genomics is well-positioned to scale its operational infrastructure and expand the reach of its diagnostic portfolio. The strategic focus will likely shift toward broadening the clinical utility of its mitochondrial assays, potentially targeting new therapeutic areas where biomarker precision is paramount. As the company navigates this enterprise-level growth phase, the emphasis will remain on securing regulatory milestones and deepening market penetration. Investors and industry stakeholders will be monitoring the firm's ability to translate its proprietary technology into widespread clinical adoption, effectively cementing its status as a cornerstone of modern genomic diagnostics.
See full Genesis Genomics company page
